Optogenetic Engineering of STING Signaling to Remotely Control anti-Tumor Immunity

Abstract

The cGAS-STING signaling pathway is regarded as a promising target for cancer therapeutics development. Here we present an ultra-light-sensitive optogenetic device, designated LiSmore for light-inducible SMOC-like repeats, that remotely control STING activation and downstream gene expression in antigen-presenting cells to mount innate immunity. We demonstrate that noninvasive light-triggered STING modulation effectively promotes dendritic cell (DC) maturation and antigen presentation, allowing T cells to be effectively sensitized to engage tumor antigens, thereby photo-boosting anti-tumor immune response. Importantly, combining LiSmore with immune checkpoint blocker (ICB) synergistically enhances antitumor effcacy in an immunosuppressive lung cancer model, which otherwise remains largely unresponsive to ICB treatment. Our findings establish that targeted optogenetic activation of STING signaling allows for the remote control of DC functions by boosting anti-tumor immunity at the tumor sites. Hence, LiSmore sets the stage for the development of wireless optogenetic immunomodulatory therapies in a light-switchable manner. Acknowledgment: This work was supported by the Welch Foundation (BE-1913-20220331 to Y.Z.), the Cancer Prevention and Research Institutes of Texas (RP210070 to Y.Z.), and the National Institutes of Health (R01GM144986 to Y.Z., R01HL134780 to R01 Y.H., R01HL146852 to Y.H., and R01CA240258 to Y.H.). Images were created by Biorender.com. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.